Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This review examined the common side effects of FGFR inhibitors like erdafitinib, pemigatinib, and futibatinib, and detailed strategies for managing them, highlighting that proactive monitoring and appropriate interventions can effectively mitigate these toxicities.

This study observed that JAK inhibitors were safe and effective for patients with moderate-to-severe alopecia areata and comorbid latent hepatitis B or stable tuberculosis, with careful monitoring and selective prophylaxis.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study found that among various JAK inhibitors for severe alopecia areata, baricitinib_4 mg demonstrated significant efficacy with high precision, while deuruxolitinib_12 mg showed the best efficacy but with wider confidence intervals, providing clinicians valuable information for treatment selection.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

In preclinical studies, topical CUR61414 reduced Hh signaling and shrank BCCs in mice, but this study found no clinical efficacy in human superficial or nodular BCCs.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.

This study aims to assess the real-world effectiveness of baricitinib, a JAK inhibitor, for promoting regrowth of nasal, genital, and beard hair in patients with severe alopecia areata, expanding on findings from the BRAVE-AA clinical trial. Results are not reported.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.